Loading
Entrada Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 21 May 2026.
Entrada Therapeutics, Inc.: what insiders have been doing
Entrada Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 37 filings came from 10 insiders.
Open-market activity splits into 3 purchases totalling €49k and 24 sales totalling €6.9M; 2 insiders sit on the buying side and 6 insiders on the selling side. Sales outweigh purchases by €6.8M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 1 senior executive. Biggest ticket of the year: €1.5M, sold by 5AM Ventures V, L.P. and made public on 18 November 2025.
The most recent open-market purchase was published on 21 May 2026, 149 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
With 37 filings in twelve months, the company is more active than the median of 19 filings across the 5,810 companies we follow on the same exchange. The full history, which starts in 2021, counts 14 purchases against 86 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 25.4 m USD and net income at -143.8 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
202
Thresholds
n/a
Buy Volume
€918,397
14 ops. · all time
Sell Volume
€10M
86 ops. · all time
Who traded when
BuySaleMPM BioVentures 2014, L.P.13 sales
MPM Bioventures 2018, L.P.13 sales
5AM Ventures V, L.P.12 sales
Kush Parmar8 sales
Kory James Wentworth5 sales
Natarajan Sethuraman4 sales
+3 other insiders
Since the insiders bought
- +15.9%Entry US$6.56 · Close at T+90 US$7.60
- +11.6%Entry US$10.12 · Close at T+90 US$11.29
- -46.6%Entry US$14.99 · Close at T+365 US$8.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.55
Analyst consensus
4 analysts1.25/5
US$11.00Target US$19.00(+318%)US$25.00
Income statement
RevenueUS$25.4M
EBITDA-US$153.8M-605% margin
Net income-US$143.8M-565.5% margin
Valuation
PER (forward)-1.5x
P/Book0.7x
Beta-0.24
Balance sheet & cash
Market capUS$177.2M
Total debtUS$50.9M
Free Cash Flow-US$129.6M
Debt / Equity21%
Profitability & ownership
ROE-54.1%
ROA-29.2%
% insiders12.2%
% institutions82.3%
Last declaration on 9 September 2026
Declarations202 total
38,500 shares@ US$7.110.11% mcap6.6% of flowCommon StockSEC:0001231919-26-001155:0
28,837 shares@ US$7.130.079% mcap5.0% of flowCommon StockSEC:0001231919-26-001155:2
192,500 shares@ US$7.410.55% mcap34.6% of flowCommon StockSEC:0001231919-26-001155:1
▼
Same trade as the filing by MPM BioVentures 2014, L.P., counted once · View ↗
38,500 shares@ US$7.110.11% mcap6.6% of flowCommon StockSEC:0001231919-26-001156:0
▼
Same trade as the filing by MPM BioVentures 2014, L.P., counted once · View ↗
192,500 shares@ US$7.410.55% mcap34.6% of flowCommon StockSEC:0001231919-26-001156:1
▼
Same trade as the filing by MPM BioVentures 2014, L.P., counted once · View ↗
28,837 shares@ US$7.130.079% mcap5.0% of flowCommon StockSEC:0001231919-26-001156:2
29,088 shares@ US$7.060.080% mcap5.0% of flowCommon StockSEC:0001231919-26-001143:0
25,131 shares@ US$7.190.070% mcap4.4% of flowCommon StockSEC:0001231919-26-001143:1
1,733 shares@ US$7.14390.0048% mcap1.9% of flowCommon StockSEC:0001725663-26-000007:0
8,724 shares@ US$7.14390.024% mcap7.1% of flowCommon StockSEC:0001613084-26-000004:0
2,528 shares@ US$7.14390.0070% mcap2.4% of flowCommon StockSEC:0001873392-26-000006:0
32,263 shares@ US$7.170.090% mcap5.6% of flowCommon StockSEC:0001231919-26-001143:2
▼
Same trade as the filing by MPM BioVentures 2014, L.P., counted once · View ↗
25,131 shares@ US$7.190.070% mcap4.4% of flowCommon StockSEC:0001231919-26-001144:1
2,079 shares@ US$7.14390.0058% mcap2.3% of flowCommon StockSEC:0001873394-26-000005:0
▼
Same trade as the filing by MPM BioVentures 2014, L.P., counted once · View ↗
29,088 shares@ US$7.060.080% mcap5.0% of flowCommon StockSEC:0001231919-26-001144:0
▼
Same trade as the filing by MPM BioVentures 2014, L.P., counted once · View ↗
32,263 shares@ US$7.170.090% mcap5.6% of flowCommon StockSEC:0001231919-26-001144:2
38,922 shares@ US$7.200.11% mcap6.8% of flowCommon StockSEC:0001231919-26-001135:0
3,733 shares@ US$7.010.010% mcap0.6% of flowCommon StockSEC:0001231919-26-001135:1
44,259 shares@ US$6.990.12% mcap7.5% of flowCommon StockSEC:0001231919-26-001135:2
▼
Same trade as the filing by MPM BioVentures 2014, L.P., counted once · View ↗
38,922 shares@ US$7.200.11% mcap6.8% of flowCommon StockSEC:0001231919-26-001136:0
▼
Same trade as the filing by MPM BioVentures 2014, L.P., counted once · View ↗
3,733 shares@ US$7.010.010% mcap0.6% of flowCommon StockSEC:0001231919-26-001136:1
▼
Same trade as the filing by MPM BioVentures 2014, L.P., counted once · View ↗
44,259 shares@ US$6.990.12% mcap7.5% of flowCommon StockSEC:0001231919-26-001136:2
▼
Same trade as the filing by MPM BioVentures 2014, L.P., counted once · View ↗
14,569 shares@ US$7.060.040% mcap2.5% of flowCommon StockSEC:0001231919-26-001106:2
21,623 shares@ US$7.340.061% mcap3.8% of flowCommon StockSEC:0001231919-26-001107:0
26,522 shares@ US$7.540.077% mcap4.8% of flowCommon StockSEC:0001231919-26-001107:1
25 of 202 declarations
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. (ticker: TRDA) is a clinical-stage biopharmaceutical company listed on the Nasdaq in the United States. Headquartered in Boston, Massachusetts, the company was founded in 2016 and went public in 2021. Its investment case is built around a differentiated scientific platform called EEV, or Endosomal Escape Vehicle, designed to help therapeutic molecules reach intracellular targets that have historically been considered difficult or inaccessible to drug. For French, Belgian, and Swiss investors, Entrada is best understood as a specialist biotechnology name: pre-commercial, innovation-driven, and highly dependent on clinical execution, but with meaningful upside if its platform continues to validate in humans.
Entrada’s core business is the discovery and development of next-generation therapies, with a particular focus on rare and severe diseases. The company’s most advanced programs are in neuromuscular disorders, especially Duchenne muscular dystrophy (DMD). Its pipeline includes several exon-skipping oligonucleotide candidates, notably ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51. Entrada is also advancing VX-670 in myotonic dystrophy type 1 (DM1) through a partnership with Vertex, and it has expanded into ophthalmology with ENTR-801, its first ocular clinical candidate for USH2A-related inherited retinal disease. That broader pipeline gives the company more than one shot on goal, while still keeping the strategic focus on difficult-to-treat genetic and neuromuscular diseases.
Read moreShow less
From a competitive standpoint, Entrada operates in a crowded biotech landscape, particularly in DMD, where it faces competition from gene therapy developers, oligonucleotide companies, and other genetic medicine platforms. Its differentiation lies in the EEV platform, which is intended to improve intracellular delivery and potentially enable better pharmacology versus conventional approaches. At the same time, investors should recognize that this remains a high-risk development company: clinical outcomes can be uncertain, regulatory timelines can shift, and additional capital may eventually be required despite the current cash runway.
Recent milestones have been important. In May 2026, Entrada reported positive topline data from Cohort 1 of its ELEVATE-44-201 study in DMD, highlighting favorable safety and tolerability together with early functional benefit. The company also stated that its cash resources should fund operations into the third quarter of 2027. In addition, Entrada said it remains on track for further clinical updates on ELEVATE-45-201 and for additional data readouts across its neuromuscular portfolio, while continuing to advance preclinical work in ophthalmology and metabolic disease. For investors monitoring SEC Form 4 insider activity, TRDA remains a classic science-led Nasdaq biotech story: high uncertainty, but with several clinically meaningful catalysts ahead.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
